Roslinct

Dentons has advised Edinburgh-based RoslinCT, a leader in advanced cell therapies contract development and manufacturing, on Global Healthcare Opportunities (GHO) Capital Partners' investment into the company. RoslinCT was established in 2006 with support from Scottish Enterprise. It was formed thro